Actively Recruiting

Phase Not Applicable
Age: 18Years - 40Years
All Genders
Healthy Volunteers
ID06412315

The Effects of Citalopram on the Brain's Response to Emotional Faces Using 7T fMRI

Led by University of Oxford · Updated on 2025-02-21

50

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating how the antidepressant citalopram affects the brain's response to emotional information, focusing on the amygdala, a key brain area involved in depression. This study explores how different parts of the amygdala react to positive and negative emotional stimuli, using advanced brain scanning technology to understand the underlying brain mechanisms. Participants will receive a single oral dose of either 20 mg citalopram or a placebo in a randomized, double-blind design. After dosing, participants will undergo high-strength 7T fMRI brain scans while viewing emotional faces. This precise imaging allows researchers to observe how citalopram influences specific subfields of the amygdala during emotional processing. Participants will be screened for medical and psychiatric health before joining. During the study, brain activity and behavioral responses such as accuracy and reaction time during a gender discrimination task will be measured about three hours after dosing. The study includes safety monitoring and lasts for a few hours on the study day, focusing on neural and behavioral outcomes related to emotional processing.

CONDITIONS

Brief Title

7T Amygdala and Citalopram Study

Who Can Participate

Age: 18Years - 40Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is willing and able to give informed consent for participation in the research
  • Sufficiently fluent English to understand and complete the task
Not Eligible

You will not qualify if you...

  • Presence of ferromagnetic objects in the body or implanted devices that may be damaged by MRI
  • Any other MRI contraindication after safety screening
  • History or current significant psychiatric illness such as major depressive disorder
  • Current or past diagnosis of significant personality disorder
  • Diagnosis of ADHD or autism spectrum disorder that impairs daily function or affects study integrity
  • Use of psychoactive medication currently or within the last 3 months
  • Use of medications that interact with citalopram currently or within the last 3 months
  • Known contraindications to citalopram including allergies, cardiovascular conditions, glaucoma, diabetes, epilepsy, or medication interactions
  • Other medical conditions that may affect safety or study integrity including seizures, brain injury, liver or kidney disease, severe gastrointestinal problems, CNS tumors, or neurological conditions
  • Clinically significant abnormal urine drug screen, pulse, or blood pressure
  • Current alcohol or substance misuse disorder
  • Body Mass Index under 18 or over 30
  • Pregnant, planning pregnancy, or breastfeeding
  • Previous participation in similar computer task studies
  • Participation in studies involving psychoactive medication or brain stimulation in last 3 months
  • Recreational drug use within last 3 months
  • Smoking more than 5 cigarettes or vaping equivalent per day
  • Consuming more than 6 caffeinated drinks per day
  • Unlikely to comply with the study protocol or unsuitable for other reasons as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single day

Participants receive a single oral dose of either citalopram or placebo.

1 dosing visit (in-person)

Monitoring

Duration - Approximately 1 hour on the day of dosing

Participants undergo 7T fMRI scanning and complete behavioral tasks approximately 3 hours after dosing to assess brain response and task performance.

1 imaging and behavioral assessment visit (in-person)

Trial Site Locations

Total: 1 location

1

University of Oxford, Department of Psychiatry

Oxford, Oxfordshire, United Kingdom, OX37JX

Actively Recruiting

Loading map...

Research Team

M

Marieke AG Martens, DPhil

C

Catherine J Harmer, DPhil

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here